Status:
ACTIVE_NOT_RECRUITING
Long-term Follow-up Gene Therapy Study for RPGR- XLRP
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
X-Linked Retinitis Pigmentosa
Eligibility:
MALE
5+ years
Brief Summary
This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLR...
Eligibility Criteria
Inclusion
- Received AAV5-hRKp.RPGR in the MGT009 Study
Exclusion
- Unwilling or unable to meet with the requirements of the study
Key Trial Info
Start Date :
July 31 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 18 2026
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04312672
Start Date
July 31 2017
End Date
November 18 2026
Last Update
December 5 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114
2
Univ of Michigan Medical Center
Ann Arbor, Michigan, United States, 48105
3
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
4
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS9 7TF